{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:19:16Z","timestamp":1793999956971,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.neurol.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:26:24Z","timestamp":1637972784000},"page":"616-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre"],"prefix":"10.1016","volume":"178","author":[{"given":"E.","family":"N\u2019kaoua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Campana-Salort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.","family":"Grapperon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mestivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.neurol.2021.10.004_bib0180","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0755-4982(04)98888-4","article-title":"Effets immunomodulateurs des immunoglobulines intraveineuses","volume":"33","author":"Guilpain","year":"2004","journal-title":"Presse Med"},{"issue":"12, Supplement 1","key":"10.1016\/j.neurol.2021.10.004_bib0185","doi-asserted-by":"crossref","first-page":"H14","DOI":"10.1016\/S0248-8663(09)73168-6","article-title":"Indications et m\u00e9canismes d\u2019action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires syst\u00e9miques","volume":"30","author":"Mouthon","year":"2009","journal-title":"Rev Med Interne"},{"issue":"8232","key":"10.1016\/j.neurol.2021.10.004_bib0190","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.neurol.2021.10.004_bib0195","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/eji.201444700","article-title":"European consensus proposal for immunoglobulin therapies","volume":"44","author":"Sewell","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neurol.2021.10.004_bib0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","article-title":"Is dosing of therapeutic immunoglobulins optimal?. A review of a three-decade long debate in europe","volume":"5","author":"Kerr","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2021.10.004_bib0205","first-page":"819","article-title":"Peut-on se passer des immunoglobulines polyclonales intraveineuses (IVIg)\u202f?","volume":"199","author":"Gay-Crosier","year":"2020","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.neurol.2021.10.004_bib0210","series-title":"La fili\u00e8re du sang en France","author":"Veran","year":"2019"},{"issue":"3","key":"10.1016\/j.neurol.2021.10.004_bib0215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ncpneuro0429","article-title":"Shortage of human intravenous immunoglobulin--reasons and possible solutions","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2021.10.004_bib0220","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2021.10.004_bib0225","doi-asserted-by":"crossref","first-page":"e0215837","DOI":"10.1371\/journal.pone.0215837","article-title":"The impacts of medication shortages on patient outcomes: a scoping review","volume":"14","author":"Phuong","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neurol.2021.10.004_bib0230","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jns.12141","article-title":"Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(\u00a9))","volume":"20","author":"Vanhoutte","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10.1016\/j.neurol.2021.10.004_bib0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"Van Nes","year":"2011","journal-title":"Neurology"},{"issue":"3S","key":"10.1016\/j.neurol.2021.10.004_bib0240","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.neurol.2021.10.004_bib0245","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"1","author":"Eftimov","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.neurol.2021.10.004_bib0250","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin: A Randomized Double-blind Clinical Trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2021.10.004_bib0255","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jnnp-2012-304670","article-title":"Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy","volume":"84","author":"Kuitwaard","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.neurol.2021.10.004_bib0260","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00415-013-6938-7","article-title":"Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?","volume":"260","author":"Rajabally","year":"2013","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2021.10.004_bib0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2021.10.004_bib0270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2021.10.004_bib0275","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2021.10.004_bib0280","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2021.10.004_bib0285","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"Van Schaik","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2021.10.004_bib0290","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2021.10.004_bib0295","first-page":"CD002062","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.10.004_bib0300","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2377-14-72","article-title":"Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern","volume":"14","author":"Eftimov","year":"2014","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2021.10.004_bib0305","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2009.08.006","article-title":"Les polyradiculon\u00e9vrites inflammatoires d\u00e9my\u00e9linisantes chroniques","volume":"31","author":"Franques","year":"2010","journal-title":"Rev Med Interne"},{"issue":"2","key":"10.1016\/j.neurol.2021.10.004_bib0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mus.22024","article-title":"Response to treatment in patients with Lewis-Sumner syndrome","volume":"44","author":"Attarian","year":"2011","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.neurol.2021.10.004_bib0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2021.10.004_bib0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2021.10.004_bib0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11940-013-0269-y","article-title":"Treatment of multifocal motor neuropathy","volume":"16","author":"Jinka","year":"2014","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2021.10.004_bib0330","first-page":"CD003217","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","volume":"2015","author":"Umapathi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.neurol.2021.10.004_bib0335","first-page":"63","article-title":"Co\u00fbt du traitement par \u00e9changes plasmatiques vs immunoglobulines intraveineuses en r\u00e9animation","volume":"38","author":"Combe","year":"2019","journal-title":"J Pharm Clin"},{"key":"10.1016\/j.neurol.2021.10.004_bib0340","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.10.004_bib0345","first-page":"CD001446","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","volume":"10","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.10.004_bib0350","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721007682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721007682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:47Z","timestamp":1758519947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378721007682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0035378721007682"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.10.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}